AGIOS PHARMACEUTICALS, INC. Weighted Average Number of Shares Outstanding, Basic and Diluted
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 69.00 million shares for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-25.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2021-02-25
- AGIOS PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-12-31 was 69.27M shares, a 8.25% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-09-30 was 69.14M shares, a 17.58% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-06-30 was 68.96M shares, a 17.43% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-03-31 was 68.61M shares, a 17.37% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 69.00M shares, a 15.01% increase from fiscal 2019.
- AGIOS PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 59.99M shares, a 4.49% increase from fiscal 2018.
- AGIOS PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2018 was 57.42M shares, a 23.25% increase from fiscal 2017.
- AGIOS PHARMACEUTICALS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2017 was 46.59M shares, a 19.07% increase from fiscal 2016.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2020-12-31 | 69.27M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | 69.21M shares derived: average of 2 quarters · filed 2021-02-25 | 69.13M shares derived: average of 3 quarters · filed 2021-02-25 | 69.00M shares 10-K · filed 2021-02-25 |
| 2020-09-30 | 69.14M shares 10-Q · filed 2020-11-05 | 69.05M shares derived: average of 2 quarters · filed 2020-11-05 | 68.91M shares 10-Q · filed 2020-11-05 | 67.68M shares derived: average of 4 quarters · filed 2021-02-25 |
| 2020-06-30 | 68.96M shares 10-Q · filed 2020-07-30 | 68.78M shares 10-Q · filed 2020-07-30 | 67.19M shares derived: average of 3 quarters · filed 2021-02-25 | 65.09M shares derived: average of 4 quarters · filed 2021-02-25 |
| 2020-03-31 | 68.61M shares 10-Q · filed 2020-04-30 | 66.30M shares derived: average of 2 quarters · filed 2021-02-25 | 63.80M shares derived: average of 3 quarters · filed 2021-02-25 | 62.53M shares derived: average of 4 quarters · filed 2021-02-25 |
| 2019-12-31 | 63.99M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | 61.40M shares derived: average of 2 quarters · filed 2021-02-25 | 60.51M shares derived: average of 3 quarters · filed 2021-02-25 | 59.99M shares 10-K · filed 2021-02-25 |
| 2019-09-30 | 58.80M shares 10-Q · filed 2020-11-05 | 58.76M shares derived: average of 2 quarters · filed 2020-11-05 | 58.66M shares 10-Q · filed 2020-11-05 | 58.54M shares derived: average of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | 58.72M shares 10-Q · filed 2020-07-30 | 58.59M shares 10-Q · filed 2020-07-30 | 58.46M shares derived: average of 3 quarters · filed 2021-02-25 | 58.35M shares derived: average of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | 58.45M shares 10-Q · filed 2020-04-30 | 58.33M shares derived: average of 2 quarters · filed 2021-02-25 | 58.23M shares derived: average of 3 quarters · filed 2021-02-25 | 58.10M shares derived: average of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | 58.20M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | 58.12M shares derived: average of 2 quarters · filed 2021-02-25 | 57.98M shares derived: average of 3 quarters · filed 2021-02-25 | 57.42M shares 10-K · filed 2021-02-25 |
| 2018-09-30 | 58.03M shares 10-Q · filed 2019-10-31 | 57.88M shares derived: average of 2 quarters · filed 2019-10-31 | 57.16M shares 10-Q · filed 2019-10-31 | 55.06M shares derived: average of 4 quarters · filed 2020-02-19 |
| 2018-06-30 | 57.72M shares 10-Q · filed 2019-08-01 | 56.71M shares 10-Q · filed 2019-08-01 | 54.07M shares derived: average of 3 quarters · filed 2020-02-19 | 52.67M shares derived: average of 4 quarters · filed 2020-02-19 |
| 2018-03-31 | 55.69M shares 10-Q · filed 2019-05-02 | 52.25M shares derived: average of 2 quarters · filed 2020-02-19 | 50.98M shares derived: average of 3 quarters · filed 2020-02-19 | 49.92M shares derived: average of 4 quarters · filed 2020-02-19 |
| 2017-12-31 | 48.80M shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | 48.63M shares derived: average of 2 quarters · filed 2020-02-19 | 48.00M shares derived: average of 3 quarters · filed 2020-02-19 | 46.59M shares 10-K · filed 2020-02-19 |
| 2017-09-30 | 48.46M shares 10-Q · filed 2018-11-01 | 47.60M shares derived: average of 2 quarters · filed 2018-11-01 | 45.85M shares 10-Q · filed 2018-11-01 | 44.90M shares derived: average of 4 quarters · filed 2019-02-14 |
| 2017-06-30 | 46.75M shares 10-Q · filed 2018-08-02 | 44.53M shares 10-Q · filed 2018-08-02 | 43.72M shares derived: average of 3 quarters · filed 2019-02-14 | 42.43M shares derived: average of 4 quarters · filed 2019-02-14 |
| 2017-03-31 | 42.28M shares 10-Q · filed 2018-05-04 | 42.21M shares derived: average of 2 quarters · filed 2019-02-14 | 40.99M shares derived: average of 3 quarters · filed 2019-02-14 | 40.23M shares derived: average of 4 quarters · filed 2019-02-14 |
| 2016-12-31 | 42.13M shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | 40.34M shares derived: average of 2 quarters · filed 2019-02-14 | 39.55M shares derived: average of 3 quarters · filed 2019-02-14 | 39.13M shares 10-K · filed 2019-02-14 |
| 2016-09-30 | 38.55M shares 10-Q · filed 2017-11-01 | 38.25M shares derived: average of 2 quarters · filed 2017-11-01 | 38.12M shares 10-Q · filed 2017-11-01 | 38.01M shares derived: average of 4 quarters · filed 2018-02-14 |
| 2016-06-30 | 37.96M shares 10-Q · filed 2017-08-08 | 37.91M shares 10-Q · filed 2017-08-08 | 37.83M shares derived: average of 3 quarters · filed 2018-02-14 | 37.75M shares derived: average of 4 quarters · filed 2018-02-14 |
| 2016-03-31 | 37.86M shares 10-Q · filed 2017-05-04 | 37.76M shares derived: average of 2 quarters · filed 2018-02-14 | 37.68M shares derived: average of 3 quarters · filed 2018-02-14 | 37.59M shares derived: average of 4 quarters · filed 2018-02-14 |
| 2015-12-31 | 37.66M shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-14 | 37.58M shares derived: average of 2 quarters · filed 2018-02-14 | 37.50M shares derived: average of 3 quarters · filed 2018-02-14 | 37.43M shares 10-K · filed 2018-02-14 |
| 2015-09-30 | 37.51M shares 10-Q · filed 2016-11-03 | 37.42M shares derived: average of 2 quarters · filed 2016-11-03 | 37.35M shares 10-Q · filed 2016-11-03 | |
| 2015-06-30 | 37.33M shares 10-Q · filed 2016-08-08 | 37.27M shares 10-Q · filed 2016-08-08 | ||
| 2015-03-31 | 37.21M shares 10-Q · filed 2016-05-09 | |||
| 2014-12-31 | 33.67M shares 10-K · filed 2017-02-16 | |||
| 2014-06-30 | 33.60M shares 10-Q · filed 2015-08-07 | 32.51M shares 10-Q · filed 2015-08-07 | 32.11M shares derived: average of 3 quarters · filed 2016-02-26 | 29.77M shares derived: average of 4 quarters · filed 2016-02-26 |
| 2014-03-31 | 31.39M shares 10-Q · filed 2015-05-11 | 31.36M shares derived: average of 2 quarters · filed 2016-02-26 | 28.49M shares derived: average of 3 quarters · filed 2016-02-26 | 22.30M shares derived: average of 4 quarters · filed 2016-02-26 |
| 2013-12-31 | 31.33M shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | 27.04M shares derived: average of 2 quarters · filed 2016-02-26 | 19.26M shares derived: average of 3 quarters · filed 2016-02-26 | 15.42M shares 10-K · filed 2016-02-26 |
| 2013-09-30 | 22.74M shares 10-Q · filed 2013-11-07 | 13.23M shares derived: average of 2 quarters · filed 2014-08-07 | 10.11M shares 10-Q · filed 2013-11-07 | 8.42M shares derived: average of 4 quarters · filed 2015-02-24 |
| 2013-06-30 | 3.72M shares 10-Q · filed 2014-08-07 | 3.69M shares 10-Q · filed 2014-08-07 | 3.65M shares derived: average of 3 quarters · filed 2015-02-24 | 3.60M shares derived: average of 4 quarters · filed 2015-02-24 |
| 2013-03-31 | 3.66M shares 10-Q · filed 2014-05-09 | 3.61M shares derived: average of 2 quarters · filed 2015-02-24 | 3.55M shares derived: average of 3 quarters · filed 2015-02-24 | 3.50M shares derived: average of 4 quarters · filed 2015-02-24 |
| 2012-12-31 | 3.56M shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | 3.50M shares derived: average of 2 quarters · filed 2015-02-24 | 3.45M shares derived: average of 3 quarters · filed 2015-02-24 | 3.40M shares 10-K · filed 2015-02-24 |
| 2012-09-30 | 3.44M shares 10-Q · filed 2013-11-07 | 3.40M shares derived: average of 2 quarters · filed 2013-11-07 | 3.35M shares 10-Q · filed 2013-11-07 | |
| 2012-06-30 | 3.36M shares 10-Q · filed 2013-09-05 | 3.30M shares 10-Q · filed 2013-09-05 | ||
| 2011-12-31 | 3.01M shares 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |